Beta Bionics faces a proposed securities class action on behalf of investors who bought its common stock between July 30, 2025, and February 24, 2026, as Hagens Berman investigates allegations that the company misled shareholders about safety complaints involving its iLet automated insulin delivery system. Investors seeking to serve as lead plaintiff have until November 3, 2026, to file a motion. The allegations center on Beta Bionics' handling of thousands of iLet complaints, including reported life-threatening hypoglycemic events, and its purported failure to investigate or report certain events to the FDA. The FDA published a January 28, 2026, warning letter to CEO Sean Saint on February 24, citing deficiencies in complaint analysis, corrective and preventive actions, and reporting of information involving deaths or serious injuries. Beta Bionics had previously described an FDA Form 483 as primarily concerning its customer-complaint handling system and said its revised systems met or exceeded agency expectations.